HemOnc Today Current Issue
The following articles appeared in the print edition of HemOnc Today.
Table of Contents
- Minimally invasive cervical cancer surgery may promote disease recurrence; professionals urge patience
-
- Would more aggressive adjuvant therapy following minimally invasive surgery help close the survival gap with open surgery?
- Second opinions in oncology: Reducing frustration John Sweetenham, MD, FRCP, FACP
- Personalized context of the cancer cell Sofia D. Merajver, MD, PhD
- Adjuvant capecitabine fails to extend survival in early-stage triple-negative breast cancer
- Gut microbial diversity before stem cell transplantation may impact survival
- Racial disparities seen in supportive care use among patients with multiple myeloma
- Rapid assignment of molecularly driven treatment feasible for acute myeloid leukemia
- Some elderly patients with breast cancer less likely to receive adjuvant chemotherapy despite OS benefit
-
- Triplet therapy shows promise in relapsed, refractory Hodgkin lymphoma
- Guideline-driven treatment fails to prolong OS among younger patients with rectal cancer
- Vaccine, nivolumab combination appears promising in recurrent HPV-related cancer
- Immediate compression offers 'clear benefit' following blood clot
- Immune checkpoint inhibitors associated with range of cardiovascular toxicities
- Liquid biopsy improves detection of targetable mutations in non-small cell lung cancer
- FDA approves Ultomiris for paroxysmal nocturnal hemoglobinuria
- FDA grants orphan drug designation to M7824 for biliary tract cancer
-
- FDA approves Herzuma, biosimilar to Herceptin, for breast cancer subset
- FDA approves romiplostim for children with immune thrombocytopenia
- FDA approves Elzonris for blastic plasmacytoid dendritic cell neoplasm
- FDA approves Asparlas for acute lymphoblastic leukemia
- FDA grants CRISPR gene therapy fast track designation for sickle cell disease